Physician profile
Boris Reznik
NPI 1710087846
$6,275.37
in general payments reported to CMS, 2019-2025
15 companies · $519 in 2025
The $519 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,031 · 2020: $687 · 2021: $1,577 · 2022: $782 · 2023: $1,181 · 2024: $499 · 2025: $519.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,114 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,114.33 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,013.79 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $916.33 | 2019-2023 | Xifaxan |
| Janssen Biotech, INC. | $781.34 | 2019-2024 | Stelara |
| Gilead Sciences, INC. | $340.93 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $302.07 | 2019-2023 | Entyvio |
| Celgene Corporation | $277.43 | 2021-2023 | Zeposia |
| Boston Scientific Corporation | $269.04 | 2019-2024 | Resolution 360 Clip, Spyglass |
| Regeneron Healthcare Solutions, INC. | $149.95 | 2023 | Dupixent |
| Intercept Pharmaceuticals, INC. | $64.99 | 2020-2021 | |
| Evoke Pharma, INC. | $44.31 | 2021 | |
| Shionogi INC | $44.20 | 2019 | |
| Madrigal Pharmaceuticals | $29.48 | 2025 | Rezdiffra |
| Merck Sharp & Dohme LLC | $16.34 | 2022 | |
| Allergan, INC. | $13.54 | 2020 | |
| Redhill Biopharma INC. | $11.63 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Boris Reznik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.